224 related articles for article (PubMed ID: 31973229)
21. Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma.
Wang CH; Wey KC; Mo LR; Chang KK; Lin RC; Kuo JJ
Asian Pac J Cancer Prev; 2015; 16(9):3595-604. PubMed ID: 25987009
[TBL] [Abstract][Full Text] [Related]
22. Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies.
Gnoni A; Licchetta A; Memeo R; Argentiero A; Solimando AG; Longo V; Delcuratolo S; Brunetti O
Medicina (Kaunas); 2019 Nov; 55(12):. PubMed ID: 31766556
[TBL] [Abstract][Full Text] [Related]
23. The use of cell free DNA in the diagnosis of HCC.
Banini BA; Sanyal AJ
Hepatoma Res; 2019; 5():. PubMed ID: 31673629
[TBL] [Abstract][Full Text] [Related]
24. Targeted therapy of hepatocellular cancer.
Wysocki PJ
Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
[TBL] [Abstract][Full Text] [Related]
25. Extracellular vesicles and their nucleic acids for biomarker discovery.
Momen-Heravi F; Getting SJ; Moschos SA
Pharmacol Ther; 2018 Dec; 192():170-187. PubMed ID: 30081050
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
[TBL] [Abstract][Full Text] [Related]
27. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
28. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies.
Cheng H; Sun G; Chen H; Li Y; Han Z; Li Y; Zhang P; Yang L; Li Y
Am J Cancer Res; 2019; 9(8):1536-1545. PubMed ID: 31497341
[TBL] [Abstract][Full Text] [Related]
29. Tumor-derived extracellular vesicles: reliable tools for Cancer diagnosis and clinical applications.
Rahbarghazi R; Jabbari N; Sani NA; Asghari R; Salimi L; Kalashani SA; Feghhi M; Etemadi T; Akbariazar E; Mahmoudi M; Rezaie J
Cell Commun Signal; 2019 Jul; 17(1):73. PubMed ID: 31291956
[TBL] [Abstract][Full Text] [Related]
30. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
31. Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future.
Stotz M; Gerger A; Haybaeck J; Kiesslich T; Bullock MD; Pichler M
Anticancer Res; 2015 Nov; 35(11):5737-44. PubMed ID: 26503994
[TBL] [Abstract][Full Text] [Related]
32. Molecularly targeted therapy in hepatocellular carcinoma.
Huynh H
Biochem Pharmacol; 2010 Sep; 80(5):550-60. PubMed ID: 20371362
[TBL] [Abstract][Full Text] [Related]
33. Extracellular Vesicles and Their Role in Urologic Malignancies.
Junker K; Heinzelmann J; Beckham C; Ochiya T; Jenster G
Eur Urol; 2016 Aug; 70(2):323-31. PubMed ID: 26924769
[TBL] [Abstract][Full Text] [Related]
34. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
Chaparro M; González Moreno L; Trapero-Marugán M; Medina J; Moreno-Otero R
Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1269-77. PubMed ID: 18808443
[TBL] [Abstract][Full Text] [Related]
35. Recent developments with immunotherapy for hepatocellular carcinoma.
Waidmann O
Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
[TBL] [Abstract][Full Text] [Related]
36. Systemic therapies in hepatocellular carcinoma: present and future.
Bertino G; Di Carlo I; Ardiri A; Calvagno GS; Demma S; Malaguarnera G; Bertino N; Malaguarnera M; Toro A; Malaguarnera M
Future Oncol; 2013 Oct; 9(10):1533-48. PubMed ID: 24106903
[TBL] [Abstract][Full Text] [Related]
37. New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions.
Chuma M; Terashita K; Sakamoto N
Hepatol Res; 2015 Oct; 45(10):E1-E11. PubMed ID: 25472913
[TBL] [Abstract][Full Text] [Related]
38. miRNAs: new tools for molecular classification, diagnosis and prognosis of hepatocellular carcinoma.
Liu AM; Wang W; Luk JM
Hepat Oncol; 2014 Jun; 1(3):323-329. PubMed ID: 30190966
[TBL] [Abstract][Full Text] [Related]
39. Extracellular Vesicle-Associated mir-21 and mir-144 Are Markedly Elevated in Serum of Patients With Hepatocellular Carcinoma.
Pu C; Huang H; Wang Z; Zou W; Lv Y; Zhou Z; Zhang Q; Qiao L; Wu F; Shao S
Front Physiol; 2018; 9():930. PubMed ID: 30065664
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
